Dupixent CTCL Lawsuit Lawyer Cutaneous T-Cell Lymphoma Claims

Medically Reviewed & Written by Dr. Shezad Malik, M.D., J.D., Board-Certified Physician & Trial Attorney

If you or a loved one were prescribed Dupixent (dupilumab) for eczema (atopic dermatitis), asthma, or nasal polyps and were subsequently diagnosed with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, or Sézary Syndrome, you may be entitled to financial compensation. Sanofi and Regeneron failed to warn patients and doctors of serious hidden risks.
Board-Certified Physician & Personal Injury, Product Liability Attorney Dr. Shezad Malik
- Free & Confidential Case Evaluation
- No Legal Fees Unless We Recover Compensation

Prescribed Dupixent and later diagnosed with Cutaneous T-Cell Lymphoma (CTCL)? Contact physician-attorney Dr. Shezad Malik for a free case evaluation today: 214-390-3189.

As both a medical doctor and personal injury lawyer, Dr. Shezad Malik provides a unique perspective in reviewing complex medical records and holding pharmaceutical manufacturers accountable.

Do You Qualify to File a Dupixent CTCL Lawsuit?

You or a family member may have grounds for a product liability claim against Sanofi and Regeneron if you meet the following criteria:

[x] Prescribed Dupixent: Received injections of dupilumab for eczema, severe asthma, chronic rhinosinusitis, or related conditions.

[x] Subsequent Cancer Diagnosis: Diagnosed with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, or Sézary Syndrome starting Dupixent therapy.

[x] Delayed Diagnosis or Progression: Experienced persistent skin lesions, rash, or plaques initially attributed to severe eczema that later proved to be T-cell lymphoma.

Note on Statutes of Limitations:</strong> Legal deadlines to file a claim vary by state. Contact our team immediately at (214) 390-3189 or submit our form for a free, confidential case evaluation before your time expires.

Why Are Lawsuits Being Filed Against the Makers of Dupixent?

Some patients prescribed Dupixent to treat eczema or other inflammatory skin conditions were later diagnosed with Cutaneous T-Cell Lymphoma CTCL. Because early symptoms of CTCL often resemble eczema, plaintiffs claim that the cancer diagnosis may have been delayed while patients continued treatment with the medication.

Dupixent is marketed as a breakthrough therapy, but emerging clinical evidence and adverse event reports reveal that Dupixent carries severe and potentially deadly risks that were omitted from or understated on the drug’s warning label:

Cutaneous T-Cell Lymphoma (CTCL): Allegations state that Dupixent alters interleukin signaling pathways (IL-4 and IL-13), suppressing initial skin symptoms while allowing underlying T-cell lymphoma to grow rapidly and go undetected.
Severe Ocular Surface Disorders (DAOSD): Including ulcerative keratitis, corneal scarring, and corneal perforation.

The Link Between Dupixent (Dupilumab) and Cutaneous T-Cell Lymphoma

Dupixent is a monoclonal antibody designed to block interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, suppressing the inflammatory response associated with atopic dermatitis. However, emerging medical literature and adverse event monitoring have raised critical concerns regarding T-cell malignancy proliferation.

1. Masking and Unmasking Early CTCL Symptoms

Early-stage Cutaneous T-Cell Lymphoma frequently presents as persistent, itchy red patches or plaques that closely mimic severe eczema. Lawsuits allege that Dupixent may suppress superficial skin inflammation while failing to treat the underlying malignant T-cells, causing a critical delay in proper biopsy and cancer diagnosis.

2. Alteration of T-Cell Signaling Pathways

Recent epidemiological studies and case series published in leading dermatology journals demonstrate an elevated relative risk of CTCL diagnoses among patients receiving dupilumab compared to non-users. Blocking specific interleukin pathways may inadvertently disrupt the body’s natural immune surveillance mechanisms against abnormal T-cell growth.

Allegations Against Dupixent Manufacturers (Sanofi & Regeneron)

Current legal actions allege that the makers of Dupixent:

Failed to adequately test dupilumab’s long-term impacts on T-cell regulation and lymphoma risk prior to widespread commercial marketing.
Failed to provide adequate warnings to prescribers and patients regarding the necessity of ruling out CTCL via skin biopsy prior to initiating therapy.
Promoted the medication as safe for long-term chronic use without alerting the medical community to post-marketing reports of rapid CTCL progression.

The Core Legal Claim: Under product liability law, drug manufacturers are legally required to disclose all known or reasonably foreseeable risks associated with their medications.

Lawsuits allege Sanofi and Regeneron prioritized billions in sales over patient safety by failing to provide adequate warnings to prescribing physicians and consumers.

One of the critical issues raised in Dupixent litigation is the similarity between early-stage CTCL and eczema. CTCL and eczema skin conditions can appear similar; the symptoms of both conditions may include:

Red, inflamed skin
Persistent chronic itching
Flaky and scaly skin patches
Thickened and roughened skin
Skin symptoms that improve and worsen over time

What is Dupixent?

Dupixent (dupilumab), manufactured by Sanofi and Regeneron Pharmaceuticals, is an injectable biologic prescribed to treat severe eczema (atopic dermatitis), asthma, chronic rhinosinusitis, eosinophilic esophagitis, and other medical conditions.

Dupixent was initially approved by the FDA in 2017 for moderate-to-severe atopic dermatitis, a common skin condition known as eczema.

Over the past few years, Dupixent has been approved to treat asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), prurigo nodularis, and several other inflammatory medical conditions.

How does Dupixent work?

Dupixent works by blocking specific immune pathways involved in inflammation and allergic responses. For many patients, Dupixent has improved symptoms when topical medications and other routine treatments fail. Dupixent is one of the world’s best-selling prescription drugs.

Scientific Data & Linked Medical Evidence

Many case reports and several clinical studies have found that the drug could “unmask” or worsen hidden lymphomas mistaken for eczema. This fact has heightened concerns that Dupixent not only failed to prevent worsening eczema symptoms but may have allowed hidden serious cancers to progress unchecked.

Cutaneous T-Cell Lymphoma (CTCL) & Mycosis Fungoides
- The Mechanism: Dupixent inhibits IL-4 and IL-13 pathways. Researchers suggest this selective immunosuppression alters cutaneous immune surveillance, potentially accelerating malignant T-cell proliferation or masking early CTCL symptoms as simple eczema flare-ups.
- Key Medical Findings:
  - FDA Safety Signal (March 2025): The FDA added Dupixent to its Potential Signals of Serious Risks list following hundreds of reported cases of T-cell lymphoma and mycosis fungoides.
  - The FDA’s Adverse Event Reporting System (FAERS) lists several hundred reports of lymphoma from Dupixent users, including many cases of cutaneous T-cell lymphoma, Sézary syndrome and other cancer subtypes.
  - According to medical experts, FDA reports are voluntary and unfortunately account for 1% to 10% of all reported injury cases, suggesting that the actual number of Dupixent CTCL cases is significantly higher.
  - Rapid Onset: Published case series indicate that many Dupixent-associated CTCL diagnoses occur within the first 12 months of starting therapy.

Significant Medical Studies

According to a study in the Journal of the American Academy of Dermatology, Dupixent users had a roughly four-times greater risk of developing cutaneous T-cell lymphoma (CTCL), a type of cancer. No increased risk was seen for other cancers. The study found that the cancer occurred more than one year after patients started taking the drug.

Another study in Dermatologic Therapy reported an increased risk of CTCL among Dupixent users. The risk was highest within the first year of treatment, and people over 60 were more susceptible.

In the journal Current Opinion in Immunology (2025), researchers concluded that while CTCL remains rare, evidence suggests that Dupixent may unmask or promote CTCL in certain patients.

A European study (March 2026) concluded that Dupilumab may unmask or exacerbate CTCL, particularly mycosis fungoides and Sézary syndrome. One year earlier, the European Respiratory Journal found that, while treatment with dupilumab for asthma resulted in significantly improved survival, it was associated with an increased risk of lymphoma, including mature T-cell and NK-cell lymphomas.

Although no single study establishes causation, plaintiffs argue that the growing body of evidence warranted stronger warnings and monitoring recommendations.

Recent Dupixent Lawsuits

In June 2026, William Douglas from Tennessee filed a lawsuit in New Jersey federal court, claimed that he developed mycosis fungoides after beginning Dupixent treatment in 2025. His lawsuit alleges that the manufacturers failed to update the medication’s warnings despite reports linking Dupixent to CTCL.

According to Douglas, the FDA issued a report in March 2025 warning of serious risks linking Dupixent to increasing rates of cancer. Douglas alleges that the manufacturers still refuse to correct the medication’s label warnings. Douglas’s doctors have advised him that he will probably need ongoing medical treatment and medical monitoring for the rest of his life.

Gabrielle Jackson, from Louisiana, filed a lawsuit in May 2026 in New Jersey federal court alleging that years of Dupixent treatment contributed to her development of CTCL. According to Ms. Jackson, she began using Dupixent for her eczema. She received Dupixent injections for five years before being diagnosed with CTCL in 2022. She reports undergoing radiation and chemotherapy following her diagnosis.

Anthony Baum from Illinois filed a lawsuit in April 2026 in Illinois federal court alleging he developed peripheral T-cell lymphoma (PTCL) within two months after beginning Dupixent treatment for severe eczema. According to Mr. Baum, he underwent chemotherapy, a stem-cell transplant, and developed additional complications. Baum claims that the companies withheld warnings for years despite case reports, epidemiological studies, and other scientific evidence linking Dupixent to T-cell lymphoma, and failed to conduct adequate testing or update the drug’s label even after cancer signals emerged.

In December 2025, Wanda Nalls filed a lawsuit in Georgia federal court, alleging she developed CTCL approximately three months after beginning Dupixent treatment for atopic dermatitis (eczema). According to Ms. Nalls, she has undergone radiation and chemotherapy treatments and faces ongoing medical care as a result of the disease.

What is Cutaneous T-cell lymphoma?

Cutaneous T-cell lymphoma is a group of closely related non-Hodgkin lymphomas that mainly affect the skin. The two most frequently diagnosed subtypes are:

Mycosis fungoides: This is the most common and generally slowest-progressing form of CTCL. MF usually begins with patches of scaly, itchy skin that resemble eczema or psoriasis, making the cancer diagnosis difficult.

Untreated and unrecognized, the cancerous T-cells infiltrate deeper layers of the skin and, in more severe stages, spread to lymph nodes or internal organs. Although mycosis fungoides is considered non-life-threatening if caught early, mycosis fungoides progression can lead to significant complications and reduced survival.

Sézary syndrome: This syndrome is a rarer and far more aggressive variant of CTCL. Sézary syndrome involves malignant T-cells circulating in the bloodstream and also affecting the skin.

Patients usually develop redness and scaling of the skin (erythroderma), severe itching, hair loss, and enlarged lymph nodes. Sézary syndrome affects both the skin and the immune system, making it harder to treat and has a poorer prognosis compared to mycosis fungoides.

While these two subtypes account for the majority of CTCL cases, other less common forms are hard to diagnose and pose treatment challenges.

Current Litigation Status

June, 2026 Update: All cutaneous T-cell lymphoma federal Dupixent lawsuits have been centralized and consolidated by the U.S. Judicial Panel on Multidistrict Litigation (JPML) in the District of New Jersey, forming MDL No. 3180.

The centralizing order transfers fifteen (15) filed cases, and another seven (7) potential tag-along actions have been identified.

The JPML Panel initiating the order found that the filed lawsuits raise similar questions about whether Dupixent may cause or accelerate CTCL, whether the drug manufacturers Sanofi and Regeneron knew or should have known about the increased risk of cancer, and whether adequate warnings were provided.

The MDL is currently focused on CTCL claims; the JPML Panel left open the possibility that lawsuits involving other T-cell lymphomas may be added later.

There are several benefits to centralizing and consolidating lawsuits before one judge, which is standard practice in nationwide personal injury and product liability claims. This process would fast-track discovery, which is expected to be immense, to avoid inconsistent rulings since a single judge would make the rulings, and allow coordinated pretrial proceedings, as additional lawsuits are expected to be filed in this growing litigation.

Qualification Checklist for Potential Clients: Do You Qualify for a Dupixent Lawsuit?

[x] Prescription History: You were prescribed Dupixent (dupilumab) for eczema, severe asthma, nasal polyps, or another approved condition.

[x] Usage Period: You used Dupixent injections for at least 30 days.

[x] Diagnosed Injury: You were subsequently diagnosed with one of the following:

Cutaneous T-Cell Lymphoma (CTCL)
Mycosis Fungoides or Sézary Syndrome
Other cancers

The MD/JD Advantage Dr. Shezad Malik Difference

Why Choose a Physician-Attorney for Your Dupixent Claim?

Pharmaceutical litigation hinges on complex medical causation—proving that Dupixent specifically caused or accelerated your cancer .

As both a practicing medical doctor and a trial attorney, Dr. Shezad Malik understands the pathology reports, biopsy results, and pharmacovigilance data from a clinical standpoint. We do not rely solely on outside consultants to interpret your medical records—we analyze the science in-house to build the strongest legal claim against corporate drug manufacturers.

Contact Dr Shezad Malik Law Firm Now for Dupixent Injuries

If you or a loved one uses Dupixent for their medical treatments and has developed T-cell lymphoma or other serious medical injuries, contact the attorneys at Dr. Shezad Malik Law Firm to learn more about your legal rights. You can speak with one of our representatives by calling 214-390-3189 or by filling out the case evaluation form on this page.

Our law firm’s principal office is in Dallas, Texas. Dr. Shezad Malik Law Firm represents clients in dangerous drug and dangerous medical device lawsuits nationwide.

Frequently Asked Questions

Q: Has the FDA recalled Dupixent due to cancer risks?

A: As of July 2026, the FDA has not issued a mandatory recall or added a black-box warning specifically for CTCL to the Dupixent prescribing label. However, regulatory authorities continue to review post-marketing safety reports, and individual lawsuits against manufacturers do not require an active FDA recall to proceed.

Q: What compensation can be recovered in a Dupixent lawsuit?

A: Victims of delayed cancer diagnosis or accelerated CTCL may seek compensation for past and future medical expenses, specialized oncology care, lost wages, loss of earning capacity, pain and suffering, emotional distress, and, in tragic cases, wrongful death damages.

Q: How much does it cost to hire a Dupixent lawyer?

A: We handle all product liability cases on a contingency fee basis. You pay nothing upfront, and we only receive a fee if we successfully win a settlement or jury verdict on your behalf.

Q: What is the Statute of Limitations for filing a Dupixent lawsuit?

A: Time limits vary by state and usually start running from the date of your diagnosis, not when you first took the medication. Because statutes of limitations can be as short as 1 to 2 years depending on your state, it is critical to contact an attorney promptly.

Q: Is there a Dupixent settlement yet?

A: Litigation is currently in the discovery and pretrial stages within federal MDL No. 3180. No global settlement has been announced yet, but individual claims are being actively prepared.

Q: What types of cancers is Dupixent associated with?

A: Several published studies have investigated whether Dupilumab use may be associated with an increased incidence of CTCL. Lawsuits focus on the possibility that Dupixent can either mask undiagnosed cancers or contribute to their progression.

The following types of cancer have been discussed in medical literature and legal claims:

Cutaneous T-Cell Lymphoma: This is the most commonly reported cancer in Dupixent users, often initially mistaken for eczema before a proper diagnosis.
Sézary Syndrome: An advanced and aggressive form of CTCL that can involve the blood and lymph nodes.
Other Non-Hodgkin Lymphomas: Some patients have reported broader lymphoma diagnoses beyond CTCL, raising questions about Dupixent’s effect on abnormal white blood cells.
NK Cell Lymphomas: Rare cancers of natural killer cells, occasionally identified in patients with Dupixent use.
Skin Cancers Misdiagnosed as Dermatitis: Early signs of lymphoma may resemble basal cell or squamous cell carcinoma, leading to diagnostic confusion and delayed treatment.